

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal

#### Lanadelumab for the long-term prevention of angioedema attacks in hereditary angioedema types I and II ID1268

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Shire Pharmaceuticals (lanadelumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Action against Allergy</li> <li>Action for sick children</li> <li>Allergy UK</li> <li>Anaphylaxis Campaign, Genetic Alliance UK</li> <li>HAE UK Patient Support</li> <li>Muslim Council of Britain</li> <li>NARA – The Breathing Charity</li> <li>National Children’s Bureau</li> <li>Primary Immunodeficiency UK</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Respiratory Nurse Specialists</li> <li>British Association of Dermatologists</li> <li>British Geriatrics Society</li> <li>British Paediatric Respiratory Society</li> <li>British Society for Allergy &amp; Clinical Immunology</li> <li>British Society for Immunology</li> <li>British Thoracic Society</li> <li>Primary Care Respiratory Society UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatrics &amp; Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare Products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>A A H Pharmaceuticals (danazol)</li> <li>Alliance Healthcare (danazol)</li> <li>Mylan (danazol)</li> <li>Sanofi (danazol)</li> <li>Sigma Pharmaceuticals (danazol)</li> <li>CSL Behring (berinert)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Cochrane Airways Group</li> <li>Cochrane Skin Group</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p>

Matrix for the technology appraisal of lanadelumab for preventing angioedema attacks in hereditary angioedema types I and II ID1268. Issue date: October 2018

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• United Kingdom Primary Immunodeficiency Network</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department for Health and Social Care</li> <li>• NHS South West Lincolnshire CCG</li> <li>• NHS Eastern Cheshire CCG</li> <li>• NHS England</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.